No Detail Found!

Efficacy and safety of MAO-B inhibitor versus donepezil in Chinese elderly stroke patients with Alzheimer disease: A potential therapeutic option

Author(s)
Huaqing Yang Department of Neurology , Central Hospital of Xinwen Mining Group Co., Ltd.,Xintai, Shandong,China
Weidong Han Department of Neurology , Central Hospital of Xinwen Mining Group Co., Ltd.,Xintai, Shandong,China
Hui Li Department of Anesthesiology, Suzhou Ninth People's Hospital,Jiangsu,China
Abstract
This pilot study designed to evaluate the efficacy and safety of MAO-B inhibitor in comparison with Donepezil (DNP) in elderly Chinese patients with Alzheimer disease (AD). In the present clinical trial, Chinese elderly patients aged =65 years with a confirmed diagnosis of AD were enrolled. The patients received MAO-B inhibitor (Selegiline 5 mg) or DNP 10 mg daily (reference) for 6 months. The efficacy and safety data were collected from 120 patients (60 patients in each group) every 3 weeks until 6 months. The primary endpoints were to assess the change in cognitive score from baseline in both the treatment group. The result of the present study showed that the patients treated with MAO-B inhibitor and DNP have similar efficacy and safety profile Considering the clinical benefit, mean (SD) improvement in sign and symptoms was numerically greater in DNP-treated patients as compared to MAO-B inhibitor at endpoint visit (SIB: 12.3 (3.7) vs 11.3 (4.2); AD severity: 14.2 (3.5); CIBIS+/CIBIC: 10.2 (2.7) vs 9.4 (3.2); ADCSADL: 14.3 (4.2) vs 13.2 (3.4); MMSE: 14.3 (3.7) vs 12.2 (3.2), P>0.05 respectively for each comparison). However, a statistical difference in terms of clinical benefit was similar between both the treatment groups (p>0.05). Overall, both the study drugs were found comparable in relieving the symptoms of AD (severity score after end of treatment: 14.2 vs 13.4 respectively; p >0.05). This indicates that MAO-B inhibitor is a potential target for the treatment of AD in China. The results of the present study may help to design a large clinical trial to evaluate the efficacy and safety of MAO-B inhibitor in comparison with DNP in AD patients.
Publication Details
Page(s) 1349-1354
Published Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 33, Issue: S3, Year: 2020

Request the full text from PASTIC

Keywords
Selective MAO-B inhibitor, selegiline, Donepezil, Post-stroke cognitive impairment
References
Adamczyk A,Jesko H,Strosznajder RP H .2005 .Alzheimer's disease related peptides affected cholinergic receptor mediated poly (ADP-ribose) polymerase activity in the hippocampus. Folia, 43(3) : 139-142.
Sharma L Alam J .2019 .Potential Enzymatic Targets in Alzheimer's: A Comprehensive Review. Curr Drug Targets., 20(3) : 316-339.
Alzheimer's Disease International .2015 .The global impact of dementia. An analysis of the prevalence, incidence, cost and trends. World Alzheimer Report, : .
Cummings N,Fox N .2017 .Defining Disease Modifying Therapy for Alzheimer's Disease. J. Prev. Alzheimers Dis, 4(2) : 109-115.
Drake C,Boutin H,Jones MS,Denes A,McColl BW,Selvarajah JR .2011 .Brain inflammation is induced by co-morbidities and risk factors for stroke. Brain. Behav, 25(6) : 1113-1122.
Feldman H,Gauthier S,Hecker J .2001 .A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology, 57(4) : 613-620.
Guzior N,Wieckowska A,Panek D,Malawska B D .2015 .Recent development of multifunctional agents as potential drug candidates for the treatment of Alzheimer's disease. Curr. Med, 22(3) : 373-404.
Maier SF,Watkins LR .1998 .Cytokines for psychologists: Implications of bidirectional immuneto-brain communication for understanding behavior, mood, and cognition. Psychol, 105(1) : 83-107.
Mitchell RA,Herrmann N,Lanctot KL .2011 .The role of dopamine in symptoms and treatment of apathy in Alzheimer's disease. CNS. Neurosci. Ther., 17(5) : 411-427.
Nakamura S,Kawamata T,Akiguchi I,Kameyama M,Nakamura N,Kimura H N .1990 .Expression of monoamine oxidase B activity in astrocytes of senile plaques. Acta. Neuropathol, 80(4) : 419-425.
O'Brien JT,Holmes C,Jones M C .2017 .Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology. J. Psychopharmacology, 31(2) : 147-168.
Reddy AP,Ravichandran J,Carcaci-Salli J .1866 .Neural regeneration therapies for Alzheimer's and Parkinson's disease-related disorders. Biochim. Biophys. Acta. Mol. Basis. Dis, : 165506.
Birks JS,Harvey RJ. .2018 .Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst. Rev., : CD001190.
Riederer P,Danielczyk W,Grunblatt E .2004 .Monoamine oxidase-B inhibition in Alzheimer's disease. Neurotoxicology., 25(1-2) : 271-277.
Rivas-Ramírez P,Roth BL,Hanizavareh SM,Blum AE .2004 .Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders. Psychopharmacology (Berl), 174(1) : 17-24.
Rothenburg LS,Herrmann N,Swardfager W,Black SE,Tennen G,Kiss A .2010 .The relationship between inflammatory markers and post stroke cognitive impairment. J. Geriatr. Psychiatry Neurol, 23(3) : 199-205.
Saura J,Luque JM,Cesura AM,Da Prada M,Chan-Palay V,Huber G .1994 .Increased monoamine oxidase B activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography. , 62(1) : 15-30.
Schedin-Weiss S,Inoue M,Hromadkova L,Teranishi Y,Yamamoto NG,Wiehager B .2017 .Monoamine oxidase B is elevated in Alzheimer disease neurons, is associated with γ-secretase and regulates neuronal amyloid β-peptide levels. Neurobiol. Aging, 9(1) : 57.
Shaw S,Bencherif M,Marrero MB M .2002 .Janus kinase 2, an early target of alpha 7 nicotinic acetylcholine receptor-mediated neuroprotection against Abeta-(1-42) amyloid. J. Biol. Chem, 277(47) : 44920-44924.
Shih JC .2018 .Monoamine oxidase isoenzymes: Genes, functions and targets for behavior and cancer therapy. J. Neural. Transm. (Vienna), 125(11) : 1553-1566.
Strosznajder RP,Jesko H .2005 .Poly(ADP-ribose) polymerase-1 is a novel nuclear target for cholinergic receptor signaling in the hippocampus. J. Physiol. Pharmacol., 56(4) : 209-213.
Winblad B,Kilander L,Eriksson S L .2006 .Donepezil in patients with severe Alzheimer's disease: Doubleblind, parallel-group, placebo-controlled study. Lancet, 367(9516) : 1057-1065.
0

Citations

0

Downloads

14

Views